Strikingly, the two clusters sharply separated both CTX-exposed Eμ-myc lymphomas for significantly different TTR (Fig. 2c), and R-CHOP-treated DLBCL patients regarding their progression-free and overall survival (PFS and OS, respectively; Fig. 2d). The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.